Industry Overview - The Medical Technology market is projected to reach US$597.00 billion by 2024, with Medical Devices expected to dominate at US$508.00 billion. The market is anticipated to grow at a steady annual rate of 5.29% from 2024 to 2029 [2][20]. Company Highlights: Aethlon Medical, Inc. - Aethlon Medical has enrolled the first patient in its clinical trial for the Hemopurifier®, aimed at treating solid tumors during anti-PD-1 therapy. This milestone was achieved on October 29, 2024, at the Royal Adelaide Hospital in Australia [3][6]. - The Hemopurifier is designed to remove life-threatening viruses and harmful exosomes from biological fluids, potentially improving therapeutic responses to anti-PD-1 therapies like Keytruda® and Opdivo® [4][6]. - Current response rates to anti-PD-1 therapies are approximately 30-40%, and the Hemopurifier aims to enhance these rates by targeting extracellular vesicles (EVs) implicated in cancer spread and therapy resistance [6][7]. Clinical Trial Details - The trial will involve approximately 9 to 18 patients, focusing on safety, feasibility, and dose-finding, with the primary endpoint being the incidence of adverse events and significant changes in safety lab tests [7][8]. - Patients will undergo a two-month run-in period with anti-PD-1 therapy, after which those not responding will receive Hemopurifier treatments [5][7]. Other Notable Developments in Medical Technology - Royal Philips has initiated the THOR IDE clinical trial, studying a combined laser atherectomy and intravascular lithotripsy catheter, which simplifies procedures for treating peripheral artery disease (PAD) [9][12]. - Microbot Medical has completed enrollment for its ACCESS-PVI clinical trial and plans to file for FDA clearance by the end of 2024 [13][14]. - BD (Becton, Dickinson and Company) has also enrolled the first patient in its AGILITY study, assessing a self-expanding vascular covered stent for PAD treatment [17][19].

SAN DIEGO, Nov. 6, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal second quarter ended September 30, 2024, at 4:15 p.m. ET on Wednesday, November 13, 2024.Management will host a conference call on Wednesday, November 13, 2024, at 4:30 p.m. ET to review financial results and recent corporate developments. Followi ...

SAN DIEGO, Oct. 8, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that James Frakes, Chief Executive Officer and Chief Financial Officer, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit, hosted by Anthony Vendetti, executive managing director and head of research at Maxim Group, on Tuesday, October 15, 2024 at 4:30 pm ET.To listen ...

Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - September 19, 2024) - Investorideas.com, a go-to investing platform, releases the second of a two-part series looking at news and developments for the treatment of cancer and solid tumors focusing on immunotherapy, featuring Aethlon Medical, Inc. (NASDAQ: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening viral infections. Aethlon's Hemopurifier® is a clinical stage immunotherapeutic dev ...

Aethlon Medical Granted Full Ethics Approval from the Medanta Institutional Ethics Committee for a Safety, Feasibility, and Dose Finding Study of its Hemopurifier® in Cancer Patients with Solid Tumors Not Responding to Anti-PD-1 AntibodiesSAN DIEGO, Sept. 19, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that, on September 9, 2024, the Medanta Institutional Ethi ...

SAN DIEGO, Sept. 17, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that management will present at the following virtual investor conferences in September:September 19-20: Life Sciences Investor Forum: James Frakes, Interim Chief Executive Officer and Chief Financial Officer and Steven LaRosa, MD, Chief Medical Officer, will present a company overview at this co ...

Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - September 17, 2024) - Investorideas.com, a go-to investing platform, releases the first of a two-part series looking at news and developments for the treatment of cancer and solid tumors featuring Aethlon Medical, Inc. (NASDAQ: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening viral infections.Read the full article at Investorideas.comhttps://www.investorideas.com/News/2024/biotech/0917 ...

Aethlon's Trial is a Safety, Feasibility, and Dose Finding Study of the Hemopurifier® in Patients with Solid Tumors Not Responding to Anti-PD-1 AntibodiesSAN DIEGO, Sept. 16, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that the Cancer Clinical Trial Unit at Royal Adelaide Hospital was activated on September 10, 2024 to begin screening and enrolling patients in ...

SAN DIEGO, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, is pleased to announce that Jim Frakes, interim CEO and CFO and Steve LaRosa, Chief Medical Officer, will present live at the Life Sciences Investor Forum, hosted by VirtualInvestorConferences.com, on September 19th 2024. DATE: September 19th TIME: 1:30 PM ETLINK: https://bit.ly/3XjDJkLAvailable for 1x1 meet ...

Aethlon Medical, Inc. (NASDAQ:AEMD) Q1 2025 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Michael Miller - Investor Relations, Rx Communications James Frakes - Interim Chief Executive Officer & Chief Financial Officer Steven LaRosa - Chief Medical Officer Conference Call Participants Marla Marin - Zacks Operator Good day, and welcome to the Aethlon Medical Fiscal First Quarter 2025 Earnings and Corporate Update Conference Call. All participants will be in listen-only mode. [Operat ...